1-3 of 3
Anthony Hamlett
Close
Sort by
Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2207.
https://doi.org/10.1182/blood-2021-148199
Published: 2021
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020
Journal Articles

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Meletios A Dimopoulos, MD, Sara Bringhen, MD, Pekka Anttila, MD, Marcelo Capra, MD PhD, Michele Cavo, MD, Craig E. Cole, MD, Cristina J Gasparetto, MD, Vania T. M. Hungria, MD PhD, Matthew Jenner, Vladimir Vorobyev, MD PhD, Eduardo Yanez Ruiz, Jianyun Yin, Anthony Hamlett, Ravi Vij, MBBS
Journal: Blood
Blood (2018) 132 (Supplement 1): 155.
https://doi.org/10.1182/blood-2018-155
Published: 2018